These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 28423668)

  • 21. Overexpression of FZD1 and CAIX are Associated with Invasion, Metastasis, and Poor-Prognosis of the Pancreatic Ductal Adenocarcinoma.
    Yang L; Yang Z; Li D; Liu Z; Zou Q; Yuan Y; Xu H
    Pathol Oncol Res; 2018 Oct; 24(4):899-906. PubMed ID: 28921449
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Correlation of laminin subunit alpha 3 expression in pancreatic ductal adenocarcinoma with tumor liver metastasis and survival.
    Xing Y; Jing X; Qing G; Jiang Y
    Radiol Oncol; 2024 Jun; 58(2):234-242. PubMed ID: 38452390
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pancreatic cancer stem cells may define tumor stroma characteristics and recurrence patterns in pancreatic ductal adenocarcinoma.
    Askan G; Sahin IH; Chou JF; Yavas A; Capanu M; Iacobuzio-Donahue CA; Basturk O; O'Reilly EM
    BMC Cancer; 2021 Apr; 21(1):385. PubMed ID: 33836674
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Increased FAT10 expression is related to poor prognosis in pancreatic ductal adenocarcinoma.
    Sun GH; Liu YD; Yu G; Li N; Sun X; Yang J
    Tumour Biol; 2014 Jun; 35(6):5167-71. PubMed ID: 24492942
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognostic significance of XB130 expression in surgically resected pancreatic ductal adenocarcinoma.
    Zhang J; Jiang X; Zhang J
    World J Surg Oncol; 2014 Mar; 12():49. PubMed ID: 24581082
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CSN6 expression is associated with pancreatic cancer progression and predicts poor prognosis.
    Shi J; Guan X; Zhan F; Liu C; Li Z; Yao Y; Wang B; Lou C; Zhang Y
    Cancer Biol Ther; 2019; 20(9):1290-1299. PubMed ID: 31311398
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Jagged1 and DLL4 expressions in benign and malignant pancreatic lesions and their clinicopathological significance.
    Huang SF; Yang ZL; Li DQ; Liu ZY; Wang CW; Miao XY; Zou Q; Yuan Y
    Hepatobiliary Pancreat Dis Int; 2016 Dec; 15(6):640-646. PubMed ID: 27919854
    [TBL] [Abstract][Full Text] [Related]  

  • 28. HBXIP protein overexpression predicts the poor prognosis of pancreatic ductal adenocarcinomas.
    Zhou X; Wang X; Duan J; Sun W; Chen Z; Li Q; Ou Z; Jiang G; Ren X; Liu S
    Pathol Res Pract; 2019 Feb; 215(2):343-346. PubMed ID: 30583814
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Low RASSF6 expression in pancreatic ductal adenocarcinoma is associated with poor survival.
    Ye HL; Li DD; Lin Q; Zhou Y; Zhou QB; Zeng B; Fu ZQ; Gao WC; Liu YM; Chen RW; Li ZH; Chen RF
    World J Gastroenterol; 2015 Jun; 21(21):6621-30. PubMed ID: 26074700
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A novel prognostic factor TIPE2 inhibits cell proliferation and promotes apoptosis in pancreatic ductal adenocarcinoma (PDAC).
    Sun Y; Cao S; Li Z; Liu X; Xu J; Tian Y; Shen S; Zhou Y
    Int J Med Sci; 2021; 18(9):2051-2062. PubMed ID: 33850476
    [No Abstract]   [Full Text] [Related]  

  • 31. Identification of ANXA1 as a lymphatic metastasis and poor prognostic factor in pancreatic ductal adenocarcinoma.
    Liu QH; Shi ML; Bai J; Zheng JN
    Asian Pac J Cancer Prev; 2015; 16(7):2719-24. PubMed ID: 25854353
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A PD-L2-based immune marker signature helps to predict survival in resected pancreatic ductal adenocarcinoma.
    Zhang Y; Xu J; Hua J; Liu J; Liang C; Meng Q; Wei M; Zhang B; Yu X; Shi S
    J Immunother Cancer; 2019 Aug; 7(1):233. PubMed ID: 31464648
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A new prognosis prediction model combining TNM stage with MAP2K4 and JNK in postoperative pancreatic cancer patients.
    Liu XD; Zhang ZW; Wu HW; Liang ZY
    Pathol Res Pract; 2021 Jan; 217():153313. PubMed ID: 33341545
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Prognostic Significance of Collagen VI in Pancreatic Ductal Adenocarcinoma.
    Kesti E; Borgmästars E; Hagström J; Mustonen H; Seppänen H; Haglund C; Sund M
    Pancreas; 2024 Oct; 53(9):e729-e738. PubMed ID: 38913551
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Programmed cell death ligand 1 cut-point is associated with reduced disease specific survival in resected pancreatic ductal adenocarcinoma.
    Tessier-Cloutier B; Kalloger SE; Al-Kandari M; Milne K; Gao D; Nelson BH; Renouf DJ; Sheffield BS; Schaeffer DF
    BMC Cancer; 2017 Sep; 17(1):618. PubMed ID: 28870260
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cystatin F as a key family 2 cystatin subunit and prognostic biomarker for early‑stage pancreatic ductal adenocarcinoma.
    Yang C; Yu T; Liu Z; Ye X; Liao X; Wang X; Han C; Zhu G; Qin W; Peng T
    Oncol Rep; 2019 Jul; 42(1):79-90. PubMed ID: 31059105
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CREPT serves as a biomarker of poor survival in pancreatic ductal adenocarcinoma.
    Yang G; Wang Y; Xiao J; Zhao F; Qiu J; Liu Y; Chen G; Cao Z; You L; Zheng L; Zhang T; Zhao Y
    Cell Oncol (Dordr); 2021 Apr; 44(2):345-355. PubMed ID: 33125631
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pancreatic cancer survival analysis defines a signature that predicts outcome.
    Raman P; Maddipati R; Lim KH; Tozeren A
    PLoS One; 2018; 13(8):e0201751. PubMed ID: 30092011
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sonic hedgehog and Gli1 expression predict outcome in resected pancreatic adenocarcinoma.
    Maréchal R; Bachet JB; Calomme A; Demetter P; Delpero JR; Svrcek M; Cros J; Bardier-Dupas A; Puleo F; Monges G; Hammel P; Louvet C; Paye F; Bachelier P; Le Treut YP; Vaillant JC; Sauvanet A; André T; Salmon I; Devière J; Emile JF; Van Laethem JL
    Clin Cancer Res; 2015 Mar; 21(5):1215-24. PubMed ID: 25552484
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Reduction of intrapancreatic neural density in cancer tissue predicts poorer outcome in pancreatic ductal carcinoma.
    Iwasaki T; Hiraoka N; Ino Y; Nakajima K; Kishi Y; Nara S; Esaki M; Shimada K; Katai H
    Cancer Sci; 2019 Apr; 110(4):1491-1502. PubMed ID: 30776178
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.